HARNESSES THE POWER OF THE IMMUNE SYSTEM

DevaCell’s ONCoat™ synthetic vector-based platform technology is enabling transformative, new therapeutic opportunities across three key segments: Oncolytic virus therapy, vaccines and gene therapy/gene editing application. The company’s lead therapeutic program is focused on applying our novel synthetic vector technology to oncolytic viral therapy. Our synthetic vector-based immunotherapeutics are designed to activate and enhance a patient’s own immune system, which enable the potential to dramatically improve patient outcomes.

TARGETED ATTACK

Our synthetic vector-based immunotherapeutics are designed to selectively attack tumor cells.

HIGHLY POTENT ATTACK

Our synthetic vector-based immunotherapeutics are designed to deliver a highly potent attack and destruction of tumor cells.

BROAD IMMUNE ACTIVATION
& ENHANCEMENT

Our synthetic vector-based immunotherapeutics are designed to activate and
enhance multiple arms of the immune system simultaneously, enabling an optimized, systemic immune response.

KEY ADVANTAGES

OnCoat™

  • Prevents Viral Neutralization
  • Enables Repeat and Systemic Delivery
  • Safety
  • Scalable
DevaCell

Designer Encapsulated Vector Assembly

Get In Touch

6650 Lusk Blvd.
Suite B105
San Diego CA 92121

info@devacell.com

Scroll to Top